uniQure N.V. (QURE)
| Market Cap | 341.37M |
| Revenue (ttm) | 111.90M |
| Net Income (ttm) | -228.47M |
| Shares Out | 47.81M |
| EPS (ttm) | -4.80 |
| PE Ratio | n/a |
| Forward PE | 27.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 736,107 |
| Open | 6.79 |
| Previous Close | 6.78 |
| Day's Range | 6.55 - 7.14 |
| 52-Week Range | 5.49 - 26.71 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 46.33 (+548.88%) |
| Earnings Date | Nov 7, 2023 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for QURE stock is "Strong Buy." The 12-month stock price forecast is $46.33, which is an increase of 548.88% from the latest price.
News
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~
CSL and uniQure Win 2023 Prix Galien USA Award
HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass.
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul
UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its work...
Gene therapy maker UniQure to cut about 20% of workforce
Dutch gene therapy maker uniQure said on Thursday it would cut about 20% of its total workforce, or about 114 jobs, and end investments in more than half of its research and technology projects to red...
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
~ Reduction of 28% of workforce not related to HEMGENIX ® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
LEXINGTON, Mass. and AMSTERDAM, Sept.
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease showing preservation of function compared to baseline and clinical benefits rela...
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~ ~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bri...
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. ("un...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $QURE #QURE--The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSIWRE / June 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. ("un...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $QURE #QURE--The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm.
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural his...
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus stand...
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an i...
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
~ Clinical update from U.S. Phase I/II trial in Huntington's disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refrac...
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
uniQure to Participate in Multiple Upcoming Industry Conferences in March
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sev...
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapy for adults with hemophilia B ~
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylact...
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated an...